Magnetic Sentinel Node and Occult Lesion Localisation (MagSNOLL)
Research type
Research Study
Full title
Magnetic Sentinel Node and Occult Lesion Localisation: A feasibility study using magnetic nanoparticles for sentinel node biopsy and localisation of occult breast cancers.
IRAS ID
126357
Contact name
Michael Douek
Contact email
Sponsor organisation
King's College London
Research summary
In the UK, breast cancer is the most common cancer in women with over 49,961 newly diagnosed patients in 2010. The implementation of breast screening programmes and diagnostic improvements have resulted in up to 35 percent of breast cancers being clinically impalpable on diagnosis. The current gold standard for the treatment of these occult lesions is excision by wire guided localisation (WGL). However, WGL has has drawbacks. Alternatives have been introduced, but these rely on radioactive materials which have cost and waste management disadvantages. We have developed a handheld magnetometer (SentiMag, Endomagnetics UK) capable of detecting a magnetic dye (Sienna +, Endomagnetics UK) injected into the breast. This technology has already been successfully applied to sentinel lymph node biopsy (SLNB) and is the subject of an NIHR-adopted, UK multicentre trial (SentiMAG Multicentre Trial; Chief Investigator Michael Douek) in breast cancer which will be followed by a randomised controlled trial. We would like to evaluate the use of the same magnetic dye (Sienna+) for both localisation of impalpable breast lesions and concurrent SLNB using the SentiMag handheld magnetometer.
REC name
London - Bromley Research Ethics Committee
REC reference
13/LO/0636
Date of REC Opinion
17 Jun 2013
REC opinion
Further Information Favourable Opinion